## Fiscal Year 2009 (FY09) Tuberous Sclerosis Complex Research Program (TSCRP) Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Clinical and Translational Research Award Go to:  Program Announcement Application Instructions and General Information Grants.gov Funding Opportunity Number: W81XWH-09-TSCRP-CTRA	Principal Investigator: Must be an independent investigator at or above the level of Assistant Professor (or equivalent).  Optional Collaborator: Must be at or above the level of Assistant Professor (or equivalent).	<ul> <li>This award may be used to support either:         <ul> <li>Clinical/translational research projects; or</li> <li>Clinical trials</li> </ul> </li> <li>Each proposal may include only one of these types of studies.</li> <li>Optional Collaborator:         <ul> <li>Collaborations that meet the criteria outlined in the Program Announcement/Funding</li> <li>Opportunity will be qualified for a higher level of funding.</li> </ul> </li> <li>Preliminary data required.</li> </ul>	<ul> <li>The maximum period of performance is 3 years.</li> <li>The maximum allowable funding for the entire period of performance is \$750,000 in direct costs (\$900,000 in direct costs if requesting an Optional Qualified Collaborator).</li> <li>Indirect costs may be proposed in accordance with your institution's negotiated rate agreement.</li> </ul>	Pre-application (LOI*): March 24, 2009 5:00 p.m. Eastern time (ET)  Application: April 14, 2009 11:59 p.m. ET
Idea Development Award Go to:  Program Announcement Application Instructions and General Information Grants.gov Funding Opportunity Number: W81XWH-09-TSCRP-IDA	Principal Investigator: Must be an independent investigator at or above the level of Assistant Professor (or equivalent).	<ul> <li>Encourage high impact, innovative research that will drive the field forward.</li> <li>Preliminary data required.</li> <li>Clinical trials not allowed.</li> </ul>	<ul> <li>The maximum period of performance is 3 years.</li> <li>The maximum allowable funding for the entire period of performance is \$450,000 in direct costs.</li> <li>Indirect costs may be proposed in accordance with your institution's negotiated rate agreement.</li> </ul>	Pre-application (LOI): March 24, 2009 5:00 p.m. ET  Application: April 14, 2009 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Career Transition Award Go to:  • Program Announcement • Application Instructions and General Information  Grants.gov Funding Opportunity Number: W81XWH-09-TSCRP- CARTA	Must be a Postdoctoral investigator with at least 2 years of postdoctoral experience.	<ul> <li>Support TSC researchers during the transition from postdoctoral training to an independent position.</li> <li>Funds the final 2 years of the postdoctoral position and the first 2 years of a faculty/independent position</li> <li>Preliminary data required.</li> </ul>	The maximum period of performance is 4 years.  The maximum allowable funding for the entire period of performance is \$338,000 in direct costs.  The maximum allowable funding is \$69,000 per year in direct costs for each postdoctoral year (years 1-2)  The maximum allowable funding is \$100,000 per year in direct costs for each faculty-level position year (years 3-4)  Indirect costs may be proposed in accordance with your institution's negotiated rate agreement.	Pre-application (LOI*): March 24, 2009 5:00 p.m. Eastern time (ET)  Application: April 14, 2009 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Exploration-Hypothesis Development Award Go to:  • Program Announcement • Application Instructions and General Information  Grants.gov Funding Opportunity Number: W81XWH-09-TSCRP-EHDA	All levels of experience.	<ul> <li>Fund the initial exploration of innovative, untested research and pursue serendipitous observations</li> <li>Preliminary data is encouraged but not required.</li> <li>Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b) or eligible for expedited review under 32CFR 219.110 or 21 CFR 56.110.</li> </ul>	<ul> <li>The maximum period of performance is 2 years.</li> <li>The maximum allowable funding for the entire period of performance is \$100,000 in direct costs.</li> <li>Indirect costs may be proposed in accordance with your institution's negotiated rate agreement.</li> </ul>	Pre-application (LOI): March 24, 2009 5:00 p.m. ET  Application: April 14, 2009 11:59 p.m. ET

<sup>\*</sup>Letter of Intent